MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$16,161K
Free Cash flow
-$25,549K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of common...
    • Maturities of short-term investm...
    • Proceeds from issuance of pre-fu...
    • Others
Negative Cash Flow Breakdown
    • Purchases of short-term investme...
    • Deferred revenue
    • Accrued liabilities and other lo...
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net income (loss)
-18,248 -26,510 -14,229 23,371
Amortization of intangible assets
37 37 36 73
Depreciation and amortization
214 473 98 659
Impairment loss on machinery and equipment
NaN -402 NaN NaN
Accretion of discounts on short-term investments
726 719 636 851
Stock-based compensation expense
4,706 1,479 1,384 3,439
Non-cash lease expense
-1,132 -1,161 -1,133 -2,189
Accounts receivable
-1,367 384 -240 -1,234
Prepaid expenses and other assets
887 874 -708 1,076
Accounts payable
67 655 419 -853
Accrued liabilities and other long-term liabilities
-3,599 486 -326 -3,209
Deferred revenue
-9,612 551 -4,375 -61,772
Net cash used in operating activities
-25,549 -23,243 -15,548 -36,796
Purchases of property and equipment
0 201 -127 146
Purchases of short-term investments
242,777 44,218 19,688 128,618
Maturities of short-term investments
50,000 30,000 20,000 83,000
Net cash (used in) provided by investing activities
-192,777 -14,419 439 -45,764
Proceeds from issuance of common stock, net issuance cost
228,351 16,262 0 93,373
Proceeds from issuance of pre-funded warrants, net issuance cost
5,855 0 NaN NaN
Proceeds from exercise of stock options
281 381 253 177
Net cash provided by financing activities
234,487 16,643 253 93,550
Net increase in cash, cash equivalents and restricted cash
16,161 -21,019 -14,856 10,990
Cash, cash equivalents and restricted cash, beginning of period
14,194 35,213 39,079 NaN
Cash, cash equivalents and restricted cash, end of period
30,355 14,194 35,213 NaN
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock, net...$228,351K Proceeds from issuance ofpre-funded warrants, net...$5,855K Proceeds from exercise ofstock options$281K Net cash provided byfinancing activities$234,487K Net increase incash, cash...$16,161K Canceled cashflow$218,326K Maturities of short-terminvestments$50,000K Stock-based compensationexpense$4,706K Accounts receivable-$1,367K Non-cash lease expense-$1,132K Depreciation andamortization$214K Accounts payable$67K Amortization of intangibleassets$37K Net cash (used in)provided by investing...-$192,777K Net cash used inoperating activities-$25,549K Canceled cashflow$50,000K Canceled cashflow$7,523K Purchases of short-terminvestments$242,777K Net income (loss)-$18,248K Deferred revenue-$9,612K Accrued liabilities andother long-term...-$3,599K Prepaid expenses andother assets$887K Accretion of discounts onshort-term investments$726K

CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics, Inc. (CTMX)